Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13672013 | 1.00 | NCF1 (0.44) | NCF1L3MBTL3L3MBTL1PLGPLAT | |
| SCHEMBL29922552 | 0.98 | NCF1 (0.43) | NCF1L3MBTL3L3MBTL1PLGPLAT | |
| SCHEMBL17508766 | 0.85 | NCF1 (0.54) | NCF1PLGPLATLMNACYP2D6 | |
| SCHEMBL15045128 | 0.83 | NCF1 (0.52) | NCF1L3MBTL3L3MBTL1PLGPLAT | |
| SCHEMBL11176985 | 0.83 | MEN1 (0.40) | NCF1LMNACYP2D6HTR6MEN1 | |
| SCHEMBL5868081 | 0.81 | NCF1 (0.50) | NCF1CYP2D6HTR6MEN1KMT2A | |
| SCHEMBL25260264 | 0.80 | SMN1; SMN2 (0.40) | NCF1L3MBTL3L3MBTL1PLGPLAT | |
| SCHEMBL1700250 | 0.80 | SMN1; SMN2 (0.40) | NCF1L3MBTL3L3MBTL1PLGPLAT | |
| SCHEMBL14013459 | 0.80 | NCF1 (0.61) | NCF1L3MBTL3L3MBTL1PLGPLAT | |
| SCHEMBL10153922 | 0.80 | NCF1 (0.45) | NCF1PLGPLATLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | NCF1 1873/4885L3MBTL3 4196/4885L3MBTL1 4151/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | NCF1 1873/4885L3MBTL3 4196/4885L3MBTL1 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.